Compare ATYR & TCBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | TCBS |
|---|---|---|
| Founded | 2005 | 1934 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 48.5M |
| IPO Year | N/A | 2021 |
| Metric | ATYR | TCBS |
|---|---|---|
| Price | $0.54 | $17.83 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 4.7K |
| Earning Date | 05-01-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | N/A | ★ 327.27 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $59.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $15.10 |
| 52 Week High | $7.29 | $20.00 |
| Indicator | ATYR | TCBS |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 67.61 |
| Support Level | $0.42 | $16.02 |
| Resistance Level | $0.59 | $18.68 |
| Average True Range (ATR) | 0.04 | 0.32 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 75.87 | 100.00 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.